Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210404 | 0.86 | COXFA4 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31026771 | 0.86 | COXFA4 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15947259 | 0.84 | MAPT (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10407993 | 0.81 | MAPT (0.44) | MAPTALDH1A1KDM4EHSD17B10GAA | |
| SCHEMBL12479388 | 0.80 | ALDH1A1 (0.57) | MAPTALDH1A1KDM4EHSD17B10GAA | |
| SCHEMBL9850219 | 0.80 | RARA (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2812534 | 0.79 | RXRA (0.52) | CA12CA1CA2CA9MAPT | |
| SCHEMBL103150 | 0.79 | MAPT (0.47) | MAPTALDH1A1RECQLKDM4EHSD17B10 | |
| SCHEMBL4516578 | 0.78 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8319042 | 0.78 | MAPT (0.39) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170850-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2014-09-24 | — | — | EP | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2170850-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-04-07 | — | — | EP | disclosed |
| EP-2014653-A1 | Novel dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008152149-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152149-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR2, S1PR5 | CA12 4411/4885CA1 3457/4885CA2 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.